Zamiri Parisa
Known title: Chief Medical OfficerCIK: 0001824806
Associated companies
Transaction History
| CALC | ▼ Sell | Other | 42,771 | — | 3/23/2023 | View on chart |
| CALC | ▼ Sell | Tax Withholding | 17,901 | $98K | 3/23/2023 | View on chart |
| CALC | ▲ Buy | Option Exercise | 120,655 | — | 3/3/2023 | View on chart |
| CALC | ▼ Sell | Tax Withholding | 42,894 | $24K | 3/3/2023 | View on chart |
| CALC | ▲ Buy | Option Exercise | 9,375 | — | 12/1/2022 | View on chart |
| CALC | ▼ Sell | Tax Withholding | 2,752 | $2K | 12/1/2022 | View on chart |
| CALC | ▲ Buy | Option Exercise | 28,125 | — | 11/24/2022 | View on chart |
| CALC | ▼ Sell | Tax Withholding | 8,255 | $6K | 11/24/2022 | View on chart |
| CALC | ▲ Buy | Option Exercise | 9,375 | — | 8/19/2022 | View on chart |
| CALC | ▼ Sell | Tax Withholding | 2,668 | $3K | 8/19/2022 | View on chart |
| CALC | ▲ Buy | Option Exercise | 37,500 | — | 5/19/2022 | View on chart |
| CALC | ▼ Sell | Tax Withholding | 13,123 | $12K | 5/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
CALC files prospectus supplement for $25M ATM offering
CalciMedica has filed a prospectus supplement to conduct an at‑the‑market offering of up to $25 million of common stock. The filing indicates the company is seeking additional capital through a public offering. The stock currently trades near its $0.59 support level, and the neutral RSI suggests no strong momentum at present. The raise could provide funding for operations but may also dilute existing shareholders.
CALC files prospectus supplement for $25M ATM offering. CalciMedica has filed a prospectus supplement to conduct an at‑the‑market offering of up to $25 million of common stock. The filing indicates the company is seeking additional capital through a public offering. The stock currently trades near its $0.59 support level, and the neutral RSI suggests no strong momentum at present. The raise could provide funding for operations but may also dilute existing shareholders.